4.8 Article

Mammary tumor induction in transgenic mice expressing an RNA-binding protein

Journal

CANCER RESEARCH
Volume 64, Issue 1, Pages 209-214

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-03-2927

Keywords

-

Categories

Funding

  1. NATIONAL CANCER INSTITUTE [R01CA078710, P30CA007175] Funding Source: NIH RePORTER
  2. NCI NIH HHS [R01-CA78710, P30-CA07175] Funding Source: Medline

Ask authors/readers for more resources

We have analyzed mammary tumors arising in transgenic mice expressing a novel, multifunctional RNA-binding protein. The protein, which we call the c-inyc mRNA coding region instability determinant binding protein (CRD-BP), binds to c-myc, insulin-like growth factor 11, and beta-actin mRNAs, and to H19 RNA. Depending on the RNA substrate, the CRD-BP affects RNA localization, translation, or stability. CRD-BP levels are high during fetal development but low or undetectable in normal adult tissues. The CRD-BP is linked to tumorigenesis, because its expression is reactivated in some adult human breast, colon, and lung tumors. These data suggest the CRD-BP is a proto-oncogene. To test this idea, the CRD-BP was expressed from the whey acidic protein (WAP) promoter in mammary epithelial cells of adult transgenic mice. The incidence of mammary tumors was 95% and 60% in two lines of WAP-CRD-BP mice with high and low relative CRD-BP expression, respectively. Some of the tumors metastasized. Nontransgenic mice did not develop mammary tumors. H19 RNA and insulin-like growth factor 11 mRNA were up-regulated significantly in non-neoplastic WAP-CRD-BP mammary, tissue. WAP-CRD-BP mice are a novel model for mammary neoplasia and might provide insights into human breast cancer biology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available